Wells Fargo & Company MN lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 254,904 shares of the biopharmaceutical company’s stock after selling 131,017 shares during the quarter. Wells Fargo & Company MN owned approximately 0.24% of Regeneron Pharmaceuticals worth $113,972,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after acquiring an additional 416,192 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 0.7% during the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after acquiring an additional 41,406 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after acquiring an additional 148,962 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock valued at $963,852,000 after acquiring an additional 29,252 shares during the last quarter. Finally, Polen Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock valued at $779,105,000 after acquiring an additional 108,413 shares during the last quarter. 66.67% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Robert E. Landry sold 663 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $498.60, for a total transaction of $330,571.80. Following the completion of the transaction, the senior vice president now directly owns 10,099 shares in the company, valued at $5,035,361.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,352 shares of company stock valued at $2,037,772. Company insiders own 10.80% of the company’s stock.

REGN has been the subject of a number of research analyst reports. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Guggenheim restated a “buy” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Morgan Stanley restated an “equal weight” rating and issued a $490.00 price target (up from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $467.84.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $373.47 on Monday. The firm has a market capitalization of $40,125.25, a P/E ratio of 32.33, a P/E/G ratio of 1.47 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/04/regeneron-pharmaceuticals-inc-regn-shares-sold-by-wells-fargo-company-mn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.